INTRODUCTION
Gynecologic malignancies account for nearly 29,000 cancer-related deaths in the United States each year; of these, carcinomas of the uterine endometrium are most common (1) . Uterine carcinomas have been classified into two primary types: estrogen dependent (type I) and nonestrogen dependent (type II; refs. 2 -5) . Type I uterine carcinomas are usually well-differentiated endometrioid adenocarcinomas that arise via a characteristic progression of glandular epithelial proliferation, with increasing degrees of atypia, to frank adenocarcinoma. They are most commonly found in premenopausal and perimenopausal women and account for the vast majority of uterine carcinomas. Type II uterine carcinomas usually exhibit serous or, less frequently, clear cell differentiation and are thought to originate from atrophic endometrium. These type II uterine carcinomas more commonly develop in older women, are clinically aggressive, and seem unrelated to estrogen exposure. Molecular analyses have shown characteristic genetic alterations and gene expression signatures in each type of uterine carcinoma (6) . For example, microsatellite instability and alterations of CTNNB1, PTEN, and K-RAS are common in type I uterine carcinoma, whereas p53 mutations are more frequent in type II uterine carcinoma (7 -11) . The dissimilar pathogenesis and clinical behavior of the two major types of uterine carcinoma have provided the basis for therapeutic strategies tailored to each type. In addition, molecularly based strategies are now being investigated in phase I and II clinical trials to target each uterine carcinoma type more precisely, including tumors of patients with advanced or recurrent disease (12) .
Ovarian carcinomas are less common than uterine carcinomas but account for the largest proportion of deaths attributable to gynecologic cancers (1) . Compared with the uterine carcinomas, less is known about ovarian cancer pathogenesis, and classification of ovarian carcinomas has traditionally been based on morphologic criteria alone. Ovarian carcinomas usually exhibit one of four major types of differentiation: serous, endometrioid, clear cell, or mucinous. Ovarian serous carcinomas account for over 50% of all ovarian carcinomas and almost always present as stage III or IV disease (13) . Ovarian endometrioid carcinomas account for f25% of all ovarian carcinomas and also often present with advanced stage disease. Mucinous and clear cell ovarian carcinomas are less common, and are more frequently confined to the ovary at the time of diagnosis. In contrast to type I (endometrioid) versus type II (serous and clear cell) uterine carcinomas, the different histologic types of ovarian carcinomas are currently treated with identical therapeutic strategies. Even recently described novel chemotherapeutic approaches do not differentiate between ovarian carcinoma subtypes (14) , despite evidence that histologic type may influence response to platinum-based first-line chemotherapy (15) .
In recent years, increasing support has been given to the hypothesis that each ovarian carcinoma subtype may represent a biologically and pathogenetically distinct entity (16 -18) . In support of this notion, and comparable to the situation in the uterine endometrium, particular genetic alterations have been found to characterize each ovarian carcinoma tumor subtype. For example, ovarian serous carcinomas show frequent mutations of p53, whereas p53 mutations are rare in all other subtypes. Similarly, although K-ras and h-catenin oncogenic mutations are uncommon in ovarian carcinoma as a group, 85% of mucinous carcinomas show K-RAS mutations and ovarian endometrioid carcinomas frequently (40%) exhibit h-catenin mutations (19 -23) . Additionally, comprehensive gene expression profiling has revealed distinctive, albeit partially overlapping, expression signatures for each ovarian carcinoma subtype (17) .
Microscopically, endometrioid and serous ovarian carcinoma subtypes are histologically similar to their counterparts in the uterus. This is perhaps not surprising, in light of the fact that all female genital tract epithelia seem to arise from the coelomic mesothelium during embryogenesis. In addition, recent molecular analyses have identified comparable genetic alterations in tumors with similar differentiation, regardless of their organ of origin. For example, microsatellite instability and PTEN and CTNNB1 mutations are frequently observed in both uterine endometrioid carcinomas and ovarian endometrioid carcinomas, whereas mutations of p53 are frequently observed in uterine serous carcinomas and ovarian serous carcinomas (9, 24 -27) . Such findings suggest that type of differentiation (e.g., endometrioid versus serous) may be at least as important as organ of origin (i.e., uterus versus ovary) in determining a given tumor's gene expression signature. If verified, this would have obvious implications for the development and implementation of novel histotype-specific strategies for treatment of ovarian cancer. In previous studies, we have shown that deregulation of a specific molecular signaling pathway (i.e., the canonical Wnt signaling pathway) is a major determinant of the gene expression pattern seen in a subset of ovarian carcinomas (i.e., the endometrioid carcinomas). Whether such defects lead to a similar gene expression signature in endometrioid-type uterine carcinomas has not yet been determined. To address relationships among histologic type, organ of origin, and Wnt pathway status in ovarian carcinomas and uterine carcinomas, we employed high-density oligonucleotide microarrays to compare gene expression profiles among 103 primary uterine and ovarian adenocarcinomas with endometrioid or serous differentiation. RNA Isolation, cDNA Synthesis, and Gene Expression Profiling. Primary tumor tissues were manually microdissected before RNA extraction to ensure that each tumor sample contained at least 70% neoplastic cells. Total RNA was extracted from frozen tissue biopsies using Trizol (Invitrogen, San Diego, CA), then further purified using RNeasy spin columns (Qiagen, Valencia, CA) according to manufacturers' protocols. Oligonucleotide microarrays [HuGeneFL arrays (7, 129 probe sets), Affymetrix, Santa Clara, CA] were used in this study. The preparation of cDNA, hybridization, and scanning of the microarrays were done according to the manufacturers' protocols, as reported previously (17, 29) . Gene expression data from the ovarian carcinomas have been previously described in detail (17) and the microarray data from these tumors and the uterine cancers are publicly available (http://dot.ped.med.umich. edu:2000/pub/Ovary/index.html). Gene expression data from the uterine carcinomas were processed using the same methods applied to the ovarian tumors. Briefly, to obtain an expression measure for a given probe set, the mismatch hybridization values were subtracted from the perfect match values, and the average of the middle 50% of these differences was used as the expression measure for that probe set. A quantile normalization procedure was done to adjust for differences in the probe intensity distribution across different chips.
MATERIALS AND METHODS
Data Processing and Statistical Analysis. The data were transformed via log 2 [max(X,1)]. Four differences were then calculated for each gene: (i) serous histotype mean minus endometrioid histotype mean within ovary, (ii) serous histotype mean minus endometrioid histotype mean within uterus, (iii) uterus organ mean minus ovary organ mean within endometrioid histotype, and (iv) uterus organ mean minus ovary organ mean within serous histotype. These differences were compared in scatterplots to assess whether in the data set as a whole, organ specific differences were invariant between histotypes, and histotype specific differences were invariant between organs. For identification of differentially expressed genes, we deemed a gene differentially expressed if it exhibited at least 2-fold mean difference and t test P < 0.05 in a given one of the four comparisons listed above. To assess significance, the number of such genes was counted for each of the four comparisons. Then the samples were randomized 1,000 times (random reassignment to histotype and organ groups), differential expression was assessed on the randomized data as described above, and the 95th and 99th percentiles for the number of differentially expressed genes in randomized data were calculated for each of the four comparisons. The observed number of differentially expressed genes was compared with the randomized percentiles for each of the four comparisons. The identical selection procedure and randomization approach was used to identify genes differentially expressed between Wnt pathwayintact and Wnt pathway -defective ovarian endometrioid carcinoma samples.
Analysis of Wnt Signaling Pathway Status. A training set of 33 well-characterized ovarian endometrioid carcinoma samples was used to form a gene expression profile distinguishing the Wnt pathway -intact samples (n = 21) from Wnt pathway -deregulated samples (n = 12). Molecular analysis of these tumors has been previously described in detail (23, 30, 31) . A graphical discriminant analysis procedure (described below) was used to determine whether gene expression differences between Wnt pathway -defective and Wnt pathway -intact uterine endometrioid carcinoma samples conformed to the ovarian endometrioid carcinoma expression profile.
Genes associated with Wnt pathway status in the ovarian endometrioid carcinoma samples were selected if they had at least a 2-fold difference between the pathway-deregulated and pathway-intact within-group means, and a t test P value for the comparison of wild-type to mutant samples was <0.05. Using these criteria, 83 marker genes associated with Wnt pathway status were identified based on the ovarian samples. In a randomization analysis of the ovarian endometrioid carcinoma samples, the average number of genes meeting the selection criteria was 12, with 95th and 99th percentiles equal to 30 and 54, respectively. This indicates that most of the 83 Wnt pathway marker genes are likely to be true positives.
Next, a two-dimensional linear projection of the 83 marker gene expression levels separating pathway-intact from pathwayderegulated ovarian endometrioid carcinoma samples was constructed as follows. Principal component analysis was used to project the expression levels of the 83 marker genes down to 20 dimensional summary vectors (accounting for 57% of the overall variation), in the same manner as done in a previous analysis of the ovarian tumors (17) . Then linear discriminant analysis was done on the 20 dimensional summaries to determine an optimal two-dimensional projection for distinguishing Wnt pathway -intact from Wnt pathway -deregulated ovarian endometrioid carcinoma samples. Because there were fewer ovarian training specimens than the number of marker genes (33 compared with 83), linear discriminant analysis was not applied directly. The uterine endometrioid carcinoma samples were then placed onto the same set of axes as the ovarian endometrioid carcinoma samples, and their locations were analyzed according to their Wnt pathway status, as determined by the presence or absence of nuclear h-catenin immunostaining. Combined analysis in which marker genes and multivariate projections are learned from both uterine endometrioid carcinoma and ovarian endometrioid carcinoma samples was not carried out due to the smaller number of uterine samples.
Immunohistochemical Analysis of h h-Catenin Expression. Five-micrometer-thick sections of formalin-fixed, paraffinembedded sections from all ovarian endometrioid carcinoma and uterine endometrioid carcinoma samples were immunohistochemically stained with mouse monoclonal anti-h-catenin antibody (Transduction Laboratories, Lexington, KY) diluted 1:500 as described previously (23) . Antigen-antibody complexes were detected with the avidin-biotin peroxidase method using 3,3V-diaminobenzidine as a chromogenic substrate (Vectastain avidin-biotin complex kit, Vector Laboratories, Burlingame, CA). Immunostained sections were lightly counterstained with hematoxylin and then examined by light microscopy. Immunoreactivity was scored independently by three observers (M.P.K., D.R.S., and K.R.C.) for the presence of nuclear versus membranous staining. Samples were designated Wnt pathway deregulated if at least 5% of cells displayed unequivocal nuclear immunoreactivity. Nuclear staining was usually accompanied by reduction or loss of the membranous staining pattern noted in Wnt pathway -intact tumor samples.
RESULTS
Type of Differentiation and Organ of Origin Both Contribute Significantly to Gene Expression Profile. Several studies have shown that gene expression profiles can be used to distinguish among many different types of cancers (32 -34) and to identify clinically relevant tumor subsets (35) . However, previous studies have also shown that highly related tumors, such as those derived from the Müllerian system, can be difficult to classify based on gene expression signature alone, particularly if histologic type is not taken into account (32) . To determine the relative contribution of organ of origin versus type of differentiation to gene expression in the most common histologic types of ovarian and uterine carcinoma, we profiled gene expression in 103 primary ovarian and uterine serous and endometrioid carcinomas, including 52 ovarian serous carcinomas, 5 uterine serous carcinomas, 33 ovarian endometrioid carcinomas, and 13 uterine endometrioid carcinomas. Details regarding the distribution of histologic type, tumor stage, and grade of the tumors studied are provided in Table 1 . Four lists of genes derived from comparisons of four pairs of tumor subgroups were generated, using 2-fold differential expression and t test P < 0.05 as selection criteria. Specifically, genes differentially expressed in ovary versus uterus within either of the two histotypes, and genes differentially expressed in serous versus endometrioid carcinomas within either organ were selected. After a randomization procedure, the 95th and 99th percentiles for the chance number of differentially expressed genes were calculated for each of the four comparisons. The observed number of differentially expressed genes was then compared with the randomized percentiles for each comparison. To the extent that more genes were selected in the actual data The observed numbers (95th percentiles) of differentially expressed genes for each comparison are shown in Table 2 Table 3 (complete lists of differentially expressed genes will be provided upon request).
Next, we wished to determine whether type of differentiation and organ of origin affect gene expression in parallel; that is, that histotype differences are similar in both organs, and organ differences are similar in both histotypes. Two scatterplots were formed; one plots uterus/ovary gene expression differences within the endometrioid carcinomas against uterus/ovary gene expression differences within the serous carcinomas (Fig. 1) . The other plots serous/endometrioid differences within the ovary against serous/endometrioid differences within uterus (Fig. 2) . For clarity, only the 1,000 most variably expressed genes are shown in each scatterplot. Both scatterplots show statistically significant correlations (r 2 = 0.18 for Fig. 1 and r 2 = 0.29 for Fig. 2 ). This indicates that many of the same genes that are specifically expressed in either serous or endometrioid tumors in the ovary tend to follow the same pattern in the uterus. Similarly, genes preferentially expressed in either ovarian or uterine tumors within the serous histotype tend to follow the same pattern in the endometrioid histotype. Collectively, these findings suggest that both type of differentiation and organ of origin contribute to gene expression profiles in the tumors studied. Interestingly, effects due to organ and to histotype are similar in magnitude and are approximately parallel in the sense that organ effects are similar in the two histotypes and histotype effects are similar in the two organs.
Ovarian and Uterine Carcinomas with Deregulated Wnt Signaling Cluster Distinctly from Samples with Intact Wnt Signaling Pathways. The canonical Wnt signaling pathway modulates many developmental and adult tissue processes, including cell fate specification, proliferation, and differentiation (36) . Wnt pathway deregulation has been shown in a number of human cancers (37). We and others have shown that ovarian endometrioid carcinomas with canonical Wnt signaling pathway defects show nuclear accumulation of stabilized h-catenin protein, usually attributable to mutations of CTNNB1, the gene encoding h-catenin, and occasionally to mutational inactivation of proteins involved in regulating levels of free cytosolic h-catenin such as APC or AXIN (23, 38, 39) . CTNNB1 mutations and nuclear accumulation of h-catenin have also been identified in a subset of uterine endometrioid carcinomas (40, 41) .
In previous work, we established that Wnt pathway status is a major determinant of global gene expression in ovarian endometrioid carcinomas (30) . In this study, we wished to determine whether a similar gene expression profile exists for both ovarian endometrioid carcinomas and uterine endometrioid carcinomas carrying Wnt pathway defects. Immunohistochemistry was done on all endometrioid samples from the ovary (previously published data; ref. 23 ) and uterus to define the pattern of intracellular h-catenin localization. Unequivocal nuclear staining was found in 36% (12 of 33) of ovarian endometrioid carcinoma samples and 31% (4 of 13) of uterine endometrioid carcinoma samples (Fig. 3) . These results are consistent with previously published data (38 -40) . Next, the training set of 33 ovarian endometrioid carcinomas (21 Wnt pathway intact, 12 Wnt pathway deregulated) was used to generate a list of 83 genes from our microarray data that were significantly associated with Wnt pathway status in the 33 ovarian endometrioid carcinomas. Of these 83 genes, only 12 are expected to be false positives as determined by our randomization analysis. We then used a multivariate statistical procedure (see Materials and Methods) to construct a graph, shown in Fig.  4 , which displays the ovarian endometrioid carcinoma samples in a way that reflects the expression of these 83 Wnt pathway marker genes. Samples lying near each other are more similar in expression of these 83 genes than those lying further apart. Coordinates in Fig. 4 combine the 83 marker gene expression levels in a way that is optimized to separate the ovarian Wnt pathway -deregulated samples from the ovarian Wnt pathwayintact samples. Importantly, the construction of these coordinate functions did not in any way reference the uterine endometrioid carcinoma data. Next, we placed the uterine endometrioid carcinoma samples on the graph, using uterine endometrioid carcinoma gene expression values and the coordinate functions developed from the ovarian endometrioid carcinoma samples. The most striking feature of Fig. 4 is that three of the uterine endometrioid carcinoma samples fall at a great distance from the other 10 uterine endometrioid carcinoma samples, lying closer to the Wnt pathway -deregulated ovarian endometrioid carcinoma (28, 43) *Next to the expected numbers indicated, upper percentiles are given in parentheses (95th percentile, 99th percentile) for the number of genes exhibiting 2-fold differential expression by chance. 
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on April 10, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from samples than the Wnt pathway -intact samples from either organ. The three ''outlier'' uterine endometrioid carcinoma samples, two of which represent different areas from the same tumor specimen, all showed nuclear accumulation of h-catenin, indicative of Wnt pathway deregulation in these cases. One uterine endometrioid carcinoma with nuclear h-catenin did not cluster with the others, which may reflect other tumor-specific genetic alteration(s) affecting gene expression. The nine uterine endometrioid carcinomas with intact Wnt signaling are generally more comparable in marker gene expression to ovarian endometrioid carcinomas with intact Wnt signaling than to either uterine endometrioid carcinomas or ovarian endometrioid carcinomas with deregulated Wnt signaling. The abscissa in Fig. 4 apparently contains the important information about Wnt pathway status, allowing separation of nearly all ovarian endometrioid carcinoma and uterine endometrioid carcinoma samples correctly according to whether Wnt signaling is intact versus deregulated. The ordinate seems to reflect gene expression changes unrelated to the status of the Wnt signaling pathway.
Although the Wnt pathway gene expression signature was initially determined exclusively using ovarian endometrioid carcinomas, it produced Wnt pathway status-related clustering of uterine endometrioid carcinomas. This indicates that gene expression alterations associated with Wnt pathway status are largely similar in endometrioid carcinomas regardless of origin in the ovary or uterus. The differential clustering of tumors with intact versus aberrant Wnt pathway status suggests that the signaling pathway acts to modulate gene expression in uterine endometrioid carcinomas, as previously shown in ovarian endometrioid carcinomas, and that gene expression profiles of Wnt pathway-deregulated tumors in the female genital tract share a considerable level of similarity to one another. Moreover, these results further support the proposal that gene expression variations in ovary and uterus are substantially parallel. Above, we noted a parallelism in histotype-specific gene expression between uterus and ovary, and here we have provided evidence of a parallelism in Wnt pathway -specific gene expression between uterus and ovary.
DISCUSSION
Advances in our understanding of the molecular heterogeneity underlying the different histologic types of uterine carcinoma has led to the recognition that each type may respond differently to specific therapeutic approaches (44, 45). Physicians and researchers are beginning to regard ovarian carcinomas in a similar light to their uterine counterparts (i.e., as a pathogenetically heterogeneous group of neoplasms that may eventually be better targeted with treatments specific to type of differentiation and genetic/biochemical features, rather than simply to organ of origin). As tumor differentiation is largely a reflection of a given tumor's genotype and gene expression signature, a major goal for the cancer field as a whole and the gynecologic cancer field in particular, is to determine which molecular alterations confer a selective advantage to tumor cells and to develop therapies targeting these specific molecular defects in the tumor cells.
This study was undertaken to determine the extent to which type of differentiation and organ of origin influence the gene expression signature of endometrioid and serous carcinomas of the female genital tract. To our knowledge, our study is the first to examine differential gene expression between the two most common histologic types of carcinoma in the uterus and ovary using high-density oligonucleotide microarrays. Most recent studies comparing genetic similarity between gynecologic carcinoma subsets have either evaluated only a limited number Fig. 2 Graphical depiction of serous/endometrioid differences within the ovary against serous/endometrioid differences within uterus. Only 1,000 genes with the greatest overall variation. Positive association (r 2 = 0.29) indicates that many of the same genes were differentially expressed between the two histologic types within both ovary and uterus. Fig. 1 Graphical depiction of uterus/ovary gene expression differences within the endometrioid carcinomas against uterus/ovary gene expression differences within the serous carcinomas. Only 1,000 genes with the greatest overall variation. Positive correlation (r 2 = 0.18) indicates that many of the same genes were differentially expressed between uterine and ovarian carcinomas within both histologic types of carcinoma. of molecular defects, or have been restricted to a single organ. We conclude that both type of differentiation and organ of origin and the status of specific molecular signaling pathways play significant roles in determining gene expression in the most common types of ovarian and uterine carcinomas.
Advances in our understanding of the clinical and molecular heterogeneity amongst ovarian carcinoma histotypes has recently prompted the creation of a dualistic model for ovarian tumorigenesis, similar to the two-type system in the uterus (18) . In the dualistic model, ovarian carcinomas are proposed to belong to one of two major categories, each corresponding to a different mode of pathogenesis. Type I ovarian carcinomas are low-grade neoplasms that progress in a stepwise fashion from borderline tumors and pursue a more indolent course; type II ovarian carcinomas are high-grade carcinomas that arise de novo and have a more aggressive course. The dualistic model is less focused on type of differentiation and more on tumor grade, although most type II carcinomas are high-grade serous carcinomas and most type I tumors are endometrioid, mucinous, and low-grade serous carcinomas. Our previous study using oligonucleotide microarrays to compare gene expression profiles in a large number of ovarian carcinomas provides some support for the dualistic model (17) . Specifically, we found that highgrade carcinomas (mostly serous) were largely separable from the low-grade (mostly endometrioid and mucinous) and clear cell neoplasms based on global gene expression.
As serous tumors account for the vast majority of ovarian cancers and are the second most common type of adenocarcinoma in the uterus, we wanted to compare gene expression profiles of tumors from both organ sites. In support of results from previous (20, 46) , our microarray data revealed that many of the genes with greater expression in uterine endometrioid carcinomas versus uterine serous carcinomas likewise show greater expression in ovarian endometrioid carcinomas versus ovarian serous carcinomas. For example, endometrioid carcinomas in either organ often highly express the MSX1, TFF3, SFN, and CEACAM1b genes. Similarly, serous carcinomas in either organ often highly express the FOLR1, PTGS1, WT1, and GAS6 genes. Recent microarray-based analysis of gene expression in uterine carcinomas also identified increased expression of FOLR1 and PTGS1 in uterine serous carcinomas compared with uterine endometrioid carcinomas (6) . Within the endometrioid carcinomas, there were statistically significant differences in gene expression between uterine and ovarian tumors. This suggests that although endometrioid carcinomas in the uterus and ovary may share some molecular defects, there are likely additional ''organ-specific'' factors that ultimately contribute to a given endometrioid carcinoma's gene expression signature.
Wnt pathway deregulation has been shown in a number of human cancers, including colorectal carcinomas (47), melanomas (48), hepatoblastomas (49) , prostatic adenocarcinomas (50, 51) , carcinomas of the uterus (40, 52) , and those of the ovary (23, 38, 53) . In both the uterus and ovary, tumors with Wnt pathway defects are usually low grade and often show squamous differentiation (23, 38, 40, 42, 53) . In our study, the uterine endometrioid carcinomas with Wnt pathway defects show a gene expression signature that is more similar to Wnt pathwaydefective ovarian endometrioid carcinomas than to carcinomas with presumptively intact Wnt signaling, regardless of organ of origin. Notably, however, the ovarian and uterine endometrioid carcinomas did not show entirely overlapping patterns of Wnt pathway status marker gene expression, again indicating a role for organ-specific effects and effects of other genetic alterations affecting gene expression.
In closing, we wish to emphasize that this study illustrates how organ of origin, type of differentiation, and specific molecular defects all contribute to gene expression in the most common types of ovarian and uterine cancers. There is increasing recognition of the fact that cancers arising within a given organ may have marked differences in their pathogenesis, clinical behavior, and response to therapy. Whereas this point is widely accepted for uterine carcinomas, it is hoped that the results of this study will help in shaping views about the importance of additional efforts to define biologically and clinically distinct subgroups of ovarian cancers.
